Compare ALG & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALG | RCKT |
|---|---|---|
| Founded | 1955 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 340.9M |
| IPO Year | 1993 | N/A |
| Metric | ALG | RCKT |
|---|---|---|
| Price | $169.88 | $3.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $225.00 | $29.12 |
| AVG Volume (30 Days) | 106.1K | ★ 1.9M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 9.64 | N/A |
| Revenue | ★ $1,615,388,000.00 | N/A |
| Revenue This Year | $1.26 | N/A |
| Revenue Next Year | $5.09 | N/A |
| P/E Ratio | $17.41 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $156.30 | $2.19 |
| 52 Week High | $233.29 | $13.35 |
| Indicator | ALG | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 48.89 | 52.07 |
| Support Level | $170.04 | $3.36 |
| Resistance Level | $175.00 | $3.64 |
| Average True Range (ATR) | 3.99 | 0.18 |
| MACD | -0.26 | 0.01 |
| Stochastic Oscillator | 26.04 | 57.30 |
Alamo Group Inc is engaged in the design, manufacture, and servicing of high-quality vegetation management and infrastructure maintenance equipment for governmental, industrial and agricultural use. Its products include tractor-mounted and self-propelled mowers, zero-turn mowers, agricultural implements, tree and branch chippers, forestry/wood recycling equipment, street and parking lot sweepers, leaf and debris collection equipment, truck mounted highway attenuator trucks, vacuum trucks, hydro-excavation equipment, telescopic boom excavators, and snow removal equipment. The company's reportable segments are Vegetation Management and Industrial Equipment. It generates a majority of revenue from Vegetation Management. Geographically, it generates the majority of revenue from United States.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.